Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis

Blood

Volumn 116, Issue 11, 2010, Pages 1839-1848

  Gupta, Vikas ^a   Tallman, Martin S ^b   He, Wensheng ^c   Logan, Brent R ^c   Copelan, Edward ^d   Gale, Robert Peter ^e   Khoury, Hanna J ^f   Klumpp, Thomas ^g   Koreth, John ^h   Lazarus, Hillard M ⁱ   Marks, David I ^j   Martino, Rodrigo ^k   Rizzieri, David A ^l   Rowe, Jacob M ^m   Sabloff, Mitchell ⁿ   Waller, Edmund K ^f   DiPersio, John F ^o   Bunjes, Donald W ^p   Weisdorf, Daniel J ^q  

^a UNIVERSITY OF TORONTO   (Canada)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e CELGENE CORPORATION   (United States)

^f EMORY UNIVERSITY HOSPITAL   (United States)

^g Fox Chase Temple BMT Program   (United States)

^h DANA FARBER CANCER INSTITUTE   (United States)

ⁱ UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^j BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^k HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^l DUKE UNIVERSITY MEDICAL CENTER   (United States)

^m RAMBAM MEDICAL CENTER   (Israel)

ⁿ UNIVERSITY OF OTTAWA   (Canada)

^o BARNES JEWISH HOSPITAL   (United States)

^p UNIVERSITY HOSPITAL ULM   (Germany)

^q UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHROMOSOME 11Q; CHROMOSOME 5; CHROMOSOME 7; CHRONIC GRAFT VERSUS HOST DISEASE; CYTOGENETICS; FEMALE; GENE REARRANGEMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK ASSESSMENT; SIBLING; SURVIVAL TIME;

EID: 77956931642     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-04-278317     Document Type: Article

References (34)

1. Yanada M, Matsuo K, Emi N, Naoe T. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer. 2005;103(8):1652-1658. (Pubitemid 40490026)
2. Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009;301(22):2349-2361.
3. Krauter J, Heil G, Hoelzer D, et al. Treatment of patients up to 60 years with high risk AML: final results of the AML SHG-Hannover 01/99 Trial [abstract]. Blood (ASH Annual Meeting Abstracts). 2006;108(11):Abstract 433.
4. Basara N, Schulze A, Wedding U, et al. Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission. Leukemia. 2009;23(4):635-640.
5. Weisdorf DJ, Anasetti C, Antin JH, et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood. 2002;99(6):1971-1977.
6. Szydlo R, Goldman JM, Klein JP, et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol. 1997;15(5):1767-1777.
7. Moore J, Nivison-Smith I, Goh K, et al. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant. 2007; 13(5):601-607.
8. Schetelig J, Bornhauser M, Schmid C, et al. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stemcell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. J Clin Oncol. 2008;26(32):5183-5191.
9. Hegenbart U, Niederwieser D, Sandmaier BM, et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol. 2006; 24(3):444-453.
10. Yakoub-Agha I, Mesnil F, Kuentz M, et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol. 2006; 24(36):5695-5702.
11. Ljungman P, Bregni M, Brune M, et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant. 2010;45(2):219-234.
12. Hubel K, Weingart O, Naumann F, Bohlius J, Wheatley K, Engert A. Allogeneic stem cell transplantation in adult patients with acute myeloid leukemia: to transplant or not to transplant? A systematic review of international guidelines [abstract]. Blood. 2009; 114(22):Abstract 1419.
13. ASBMT Position Statement. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in adults. Biol Blood Marrow Transplant. 2008;14(2): 135-136.
14. Sierra J, Martino R, Sanchez B, Pinana JL, Valcarcel D, Brunet S. Hematopoietic transplantation from adult unrelated donors as treatment for acute myeloid leukemia. Bone Marrow Transplant. 2008;41(5):425-437. (Pubitemid 351395096)
15. Milligan DW, Grimwade D, Cullis JO, et al. Guidelines on the management of acute myeloid leukaemia in adults. Br J Haematol. 2006;135(4): 450-474.
16. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood. 2010;115(3):453-474.
17. Flomenberg N, Baxter-Lowe LA, Confer D, et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood. 2004;104(7):1923-1930.
18. Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007;110(13):4576-4583.
19. Petersdorf EW, Gooley TA, Anasetti C, et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood. 1998;92(10):3515-3520. (Pubitemid 28525174)
20. Weisdorf D, Spellman S, Haagenson M, et al. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transplant. 2008;14(7):748-758.
21. Giralt S. Reduced-intensity conditioning regimens for hematologic malignancies: what have we learned over the last 10 years? Hematology Am Soc Hematol Educ Program. 2005:384-389.
22. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96(13):4075-4083.
23. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15(6):825-828.
24. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus- host disease. Biol Blood Marrow Transplant. 2003;9(4):215-233.
25. Klein J, Moeschberger M. Survival Analysis: Techniques of Censored and Truncated Data. 2nd ed. New York, NY: Springer-Verlag; 2003.
26. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;4:187-200.
27. Cornelissen JJ, van Putten WL, Verdonck LF, et al. Results of a HOVON/SAKK donor versus nodonor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middleaged adults: benefits for whom? Blood. 2007; 109(9):3658-3666.
28. Suciu S, Mandelli F, de Witte T, et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood. 2003;102(4):1232-1240.
29. Ringden O, Pavletic SZ, Anasetti C, et al. The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood. 2009;113(13):3110-3118.
30. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92(7):2322-2333.
31. Breems DA, Van Putten WL, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008;26(29):4791-4797.
32. Ringden O, Labopin M, Gorin NC, et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2004;22(3):416-423.
33. Khoury HJ, Loberiza FR Jr, Ringden O, et al. Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. Blood. 2006;107(4):1712-1716.
34. Dekker A, Bulley S, Beyene J, Dupuis LL, Doyle JJ, Sung L. Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. J Clin Oncol. 2006;24(33):5207-5215. (Pubitemid 46631364)